Company news

Faron Pharmaceuticals Oy news in 2025

Faron Pharmaceuticals Oy's news releases, calls and decks from 2025, newest first.

View company

Faron Announces Publication of Full Phase I BEXMAB Study Data in Lancet Haematology

May 30, 2025

Faron announces publication of full Phase I B...

May 30, 2025

Faron Pharmaceuticals Ltd: Issue of Treasury...

May 27, 2025

Faron’s Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies

May 27, 2025

Faron’s Bexmarilimab demonstrates immune-acti...

May 27, 2025

Faron Announces New Data that Highlight Patient Populations with Cancer that are Most Likely to Benefit from First-in-class Immunotherapy Bexmarilimab

May 23, 2025

Faron announces new data that highlight patie...

May 23, 2025

Faron Pharmaceuticals: Strengthens its busine...

May 21, 2025

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

May 21, 2025

Faron Appoints Ralph Hughes as Chief Business...

May 21, 2025

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

May 15, 2025

Faron Announces Acceptance of Bexmarilimab Da...

May 15, 2025

Faron Pharmaceuticals Presents Promising Phase 1/2 Data from BEXMAB Study at MDS 2025 Plenary Session

May 12, 2025

Faron Pharmaceuticals presents promising Phas...

May 12, 2025

Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025

April 24, 2025

Faron announces acceptance of bexmarilimab Ph...

April 24, 2025

Holding in Company

April 17, 2025

Faron Pharmaceuticals - Positive phase II BEX...

April 15, 2025

Faron Pharmaceuticals: Positive data from BEX...

April 15, 2025

Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome

April 15, 2025

Inside Information: Faron Announces Positive...

April 15, 2025

Faron Pharmaceuticals: Enters into convertibl...

April 3, 2025

Inside Information: Faron enters into an up t...

April 3, 2025

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

March 27, 2025

Board Changes

March 21, 2025

Results of the Annual General Meeting, Change of Directors, Decision of the Board Meeting After the AGM

March 21, 2025

Results of the Annual General Meeting, Change...

March 21, 2025

Shareholders’ Nomination Board updates its Recommendation on the Number of Board Members to be Elected and the Persons Proposed to be Elected

March 20, 2025

Shareholders’ Nomination Board updates its re...

March 20, 2025

FDA Grants Orphan Drug Designation

March 3, 2025

Notice of Annual General Meeting

February 28, 2025

Positive EMA Opinion on Orphan Drug Designation

February 27, 2025

Annual Report 2024 published

February 27, 2025

Financial Statement 1 January to 31 December 2024

February 27, 2025

Notice of Financial Statement and Annual Report

February 19, 2025

Holding(s) in Company

February 14, 2025

Change of Broker

February 11, 2025

Results of Oversubscribed Placing

February 6, 2025

Proposed Issue and Placing

February 5, 2025

Final Patient Identified for BEXMAB Phase II Study

January 31, 2025

← Newer news releases

Decks in 2025